Clinical Study On Treatment Of Nonalcoholic Fatty Liver Disease With Huangqi Jiangzhi Decoction

PurposePreliminary summary Lv Wenliang chief physician understanding of the basic pathogenesis of nonalcoholic fatty liver disease, dialectical thinking, diagnosis and treatment experience and characteristics of the drug. Astragalus membranaceus lipid-lowering soup on the clinical efficacy of nonalcoholic fatty liver disease, in order to demonstrate the effectiveness of the experience side, and astragalus membranaceus lipid-lowering decoction on nonalcoholic fatty liver disease specific utility of biochemical indicators and clinical symptoms. For traditional Chinese medicine treatment of nonalcoholic fatty liver disease and effective way to provide the theoretical material.MethodsUse prospective controlled clinical research method before and after its 60 patients with nonalcoholic fatty liver disease in clinical curative effect observation, give astragalus membranaceus lipid-lowering soup base, after 12 weeks of treatment, respectively, before treatment, treatment of 6 weeks,12 weeks of treatment observation records of the patient’s symptoms and signs, before treatment, after treatment observation records of patients with liver function, blood fat index, abdominal ultrasound and related safety indicators, using SPSS20.0 statistical analysis software to carry on the analysis, in order to evaluate its effect.ResultsPreliminary summarized Lv Wenliang chief physician’s clinical experience in the treatment of nonalcoholic fatty liver disease, with 7 summarizes the spleen wet, phlegm and remove blood stasis as basic treatment of the experience of the party (astragalus membranaceus lipid-lowering soup), clinical disease, firmly when using astragalus membranaceus lipid-lowering soup as basic party with add and subtract. Careful with strict, in terms of drug use and peaceful, good medicine edible medicine, excellent compatibility, good medicine for.In terms of improving symptom integral:treatment of 6 weeks,12 weeks of treatment, the symptoms always points compared to the baseline before treatment was statistically significant (P<0.05); 6 weeks,12 weeks of treatment, the symptoms points compared to the baseline before treatment was statistically significant (P<0.05). In the aspect of improving liver function, ALT and AST compared to the baseline before treatment after treatment was statistically significant (P<0.05); GGT compared to the baseline before treatment after treatment with no statistical significance (P<0.05). TG:in terms of lipid improve after treatment compared with the baseline before treatment (P<0.05); CHO, after treatment in HDLC, LDLC compared to the baseline before treatment has no statistical significance (P<0.05). Improvements in ultrasonic:after treatment there was no statistically significant difference compared with ultrasonic score before treatment (P<0.05).ConclusionAstragalus membranaceus lipid-lowering soup can significantly improve the clinical symptoms in patients with NAFLD. Astragalus membranaceus lipid-lowering soup can improve the ALT, AST, GGT, etc, which are the indices of liver function, effect of ALT and AST. Astragalus membranaceus lipid-lowering soup to CHO, TG have certain improvement effect, the effect is not significant, in HDLC, LDLC no improvement. The ultrasound results astragalus lipid-lowering soup can improve patients.